# Hyfinity Investments

> Hyfinity Investments is a VC fund backing Biotechnology and Medical. See 17 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Chaoyang, China
- Total investments: 17
- Last investment: Aug 2025
- Lead investor: 59%
- Last updated: Aug 2026
- Website: http://www.hyfinityfund.com/

Hyfinity Investments is a VC fund in Chaoyang focused on Biotechnology and Medical. Huiding Investment brings together a team of senior partners in China's top investment institutions, and is built by a team with years of experience in entrepreneurial operations, overseas technology China's experience and industry resources. Huiding is committed to integrating global medical technology innovation, focusing on theupgrading of China's medical industry, pooling resources, helping each other, and supporting Chinese companies to become industry leaders.

## Contacts

5 contacts available for Hyfinity Investments. Shizune tracks 1 team members at Hyfinity Investments. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/hyfinity-investments?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 9 | 53% |
| Medical | 7 | 41% |
| Health Care | 7 | 41% |
| Pharmaceutical | 4 | 24% |
| Biopharma | 2 | 12% |

12 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 4 | 24% |
| Series B | 4 | 24% |
| Series C | 4 | 24% |
| Seed | 3 | 18% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| China | 11 | 65% |
| Iceland | 1 | 6% |
| Singapore | 1 | 6% |
| United States | 1 | 6% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Dr. Sylvia Xin He | Managing Partner and Founder | 5 | https://shizune.co/investors/profile/xin-he-4171 |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Huiyun Biotechnology | Huiyun Biotechnology, referred to as "Huayun Bio", was founded by an internationally renowned metabolomics research team returning to China. It is a company dedicated to developing and providing chronic disease diagnosis and early warning. National high-tech enterprises for innovative technologies and solutions and interventions. Atpresent, Huiyun Bio has a series of in vitro diagnostic kits, intelligent auxiliary software, and health drinks with independent intellectual property rights, and provides a number of scientific research and medical inspection services. |  | Series A | Aug 28, 2025 |  |
| ZD Medical | ZD Medical develops phase variance optical coherence tomography that can detect macular degeneration and retinal microvascular proliferation caused by diabetes at the same time. It is a non-invasive, early-detection technology for diabetic retinopathy. ZD Medical's phase variance optical coherence tomography can detect both maculardegeneration and retinal microvascular proliferation caused by diabetes. ZD Medical brings together scientific and technological elites from both at home and abroad to pursue the development and manufacture of high-quality medical devices, and is dedicated to providing practical overall solutions for medical diagnosis and clinical treatment in order to benefit humanity's medical and health causes. | $14M | Series C | Nov 01, 2024 |  |
| Delova Biotech | Delova Biotech specializes in the field of pain treatment. It uses the company's rich R&D experience and special preparation technology platform to improve existing drugs and conduct research and development of improved new analgesics in China and the United States. | $13.8M | Series B | Apr 02, 2024 |  |
| Digital Precision Medical (DPM) | DPM's business scope includes several series of high-end intraoperative optical molecular imaging surgical navigation equipment and contrast agents developed and produced independently. Digital Precision Medical product lines are primate MPI-CT fusion, multimodal imaging system, near-infrared region ii, full spectrum, smart eye h280, 4Kfluorescence-hui yan h3800, and super eye c1000. The products are used for various surgical procedures and have the benefits of high sensitivity, high-definition fidelity, and ease of operation. | $27.8M | Series C | Jan 22, 2024 |  |
| Best-Link Bioscience | Best-Link Bioscience is a high-tech enterprise engaged in innovative drug research and development, focusing on cutting-edge scientific discovery, advanced therapeutic technologies, and the creation of novel medicines to address unmet clinical needs and improve patient outcomes worldwide. | $29.1M | Series A | Apr 04, 2023 |  |
| Neomodulus | Nuoyimeier is a developer of implantable consumables. |  | Series B | Mar 07, 2023 |  |
| Immunowake | Immunowake is a biotechnology company that focuses on identifying new therapies for patients who do not respond to existing immunotherapies. Immunotherapy involves harnessing the body’s immune system to identify and kill cancer cells in the same way pathogens are identified and targeted. Recent breakthroughs in cancer immunotherapy havedemonstrated that powerful anti-tumor responses can be achieved by activating antigen-specific T-cells. | $20M | Series A | May 15, 2022 |  |
| InxMed | InxMed is a clinical-stage biotech company focusing on developing "Best-in-Disease Combination" medicines to bring novel treatment options for patients. Our innovations are inspired by patients and driven by an in-depth understanding of disease biology and pharmacology. InxMed is committed to building a translational platform equippedwith global-level top-notch know-how and efficient execution capabilities. | $15M | Series B | May 08, 2022 |  |
| Cargene | Founded in 2020, Cargene Biopharma is a preclinical-stage biopharmaceutical company developing innovative oligonucleotide therapeutics for liver fibrosis and ophthalmic disorders, with operations in Singapore, USA and China. Cargene uses proprietary platforms backed by novel biology and chemistry insights, Cargene aims to improve quality of lifefor millions of patients worldwide through creating highly specific, stable and potent nucleic acid-based medicines for the treatment of a broad range of diseases. | $19.2M | Seed | Dec 14, 2021 |  |
| Carcell Biopharma | Carcell Biopharma is a pre-clinical biotech company. Carcell Biopharma develops cell and gene therapy products with an innovative cross-border business model. | $15.6M | Seed | Nov 01, 2021 |  |

10 of 17 investments shown.

## Co-investors
- [Bay City Capital](https://shizune.co/investors/profile/bay-city-capital) — VC Fund, 2 deals together
- [BioTrack Capital](https://shizune.co/investors/profile/biotrack-capital) — VC Fund, 2 deals together
- [BVCF](https://shizune.co/investors/profile/bioveda-china-fund) — VC Fund, 2 deals together
- [CDH Investments](https://shizune.co/investors/profile/cdh-investments) — VC Fund, 2 deals together
- [Earlybird Venture Capital](https://shizune.co/investors/profile/earlybird-venture-capital) — VC Fund, 2 deals together
- [Innovation and Technology Venture Fund](https://shizune.co/investors/profile/innovation-and-technology-venture-fund) — VC Fund, 2 deals together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Hyfinity Investments invest in?

Hyfinity Investments invests primarily in Biotechnology, Medical and Health Care startups, most often at Series A and Series B stage. Most of the 17 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Hyfinity Investments?

Public channels for Hyfinity Investments include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Hyfinity Investments?

The team at Hyfinity Investments includes Dr. Sylvia Xin He (Managing Partner and Founder). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co